References
- Grimm E A, Mazumder A, Zahng H Z, Rosenberg S A. The lymphokine activated killer cell phenomenon: Lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1983; 155: 1823–41
- Cheever M A, Greenberg P D, Fefer A, Gillus S A. Augmentation of the anti-tumor therapeutic efficacy of longterm cultured T-lymphocytes by in vivo administration of purified interleukin2. J Exp Med 1982; 155: 968–80
- Mule J J, Shu S, Schwarz S L, Rosenberg S A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin 2. Science 1984; 225: 1487–9
- Rosenberg S A. Immunotherapy of cancer by the systemic administration of lymphoid cells plus interleukin2. J Bil Res Mod 1984; 3: 501–11
- Itoh K, Tilden A B, Kumagai K, Balch C M. Leu-11 lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin2 (rIL-2)-induced activated killer (AK) cells. J Immunol 1985; 134: 802–7
- Timonen T, Ortaldo J R, Herberman R B. Characteristics of human large granular lymphocytes and relationship to natural killer and killer cells. J Exp Med 1981; 153: 569–82
- Ebbers J, Lindenberger J, Meyer zum Gottesberge A, Koldovsky P, Koldovsky U, Vosteen K H. Carcinoma into athymic mice. ORL 1986; 48: 1–7
- Zenner H P, Lehner W, Hermann I F. Establishment of cell lines from larynx and submandibular gland carcinoma. Arch Otorhinolaryngol 1979; 225: 269–77
- Bogden A E, Haskell P M, Le Page D J, Kelton D E, Cobb W R, Esber H J. Growth of human xenografts implanted under the renal capsule of normal immunocompetent mice. Exp Cell Biol 1979; 47: 281–93
- Oldham R B, Smalley R V. Immunotherapy: the old and new. J Bil Re Mod 1983; 2: 1–37
- Naito S, Von Eschenbach A C, Fidler I J. Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice. J Nat Cancer Inst 1987; 78: 377–85
- Nomori H, Saijo N, Hyoi M, Inomata M, Shimizu E, Kanzawa F, Hoshi A. Detection of NK activity of lymphocytes by human tumor clonogenic assay—its correlation with the 5Cr-release assay. Int J Cancer 1985; 35: 449–55
- Grimm E A, Ramsay K M, Mazumder A, Wilson D J, Rosenberg S A. Lymphokine activated killer phenomenon. II. Precursor phenotype is serologically distinct from peripheral blood T lympho-324 H. Kumazawa et al Acta Otolaryngol (Stockh) 180 cytes, memory cytotoxic thymus derived lymphocytes and natural killer cells. J Exp Med 1983; 157: 884–7
- Ferrini S M, Moretta L, Pantaleo G, Moretta A. Surface markers of human lymphokine-activated killer cells and their precursors. Analysis at the population and clonal level. Int J Cancer 1987; 39: 18–24
- Lanier L L, Benike J, Phillips J H, Engleman E G. Recombinant interleukin2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J Immunol 1985; 134: 794–801
- Ortald J R, Mason A, Overton R. Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 1986; 164: 1193–1205
- Sawada H, Abo T, Sugawara S, Kumagai K. Prerequisite for the induction of lymphocyte-activated killer cells from T lymphocytes. J Immunol 1988; 140: 3668–73
- Rosenberg S A, Mule L L. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin2. Surgery 1985; 98: 437–47
- Kürten C, Kau R, Kumazawa H, Koldovsky P. Antitumoral effect of in vitro with tumor stimulated autologous peripheral blood lymphocytes measured by subrenal capsule assay. Arch Otorhinolaryngol 1989, [in press].
- Kau R, Kürten C, Kumazawa H, Koldovsky P. Antibody dependent cellular cytotoxicity (ADCC) against tumor of head and neck region measured by subrenal capsule assay. Arch Otorhinolaryngol 1989, [in press].